Close Menu

NEW YORK – On Monday, clinical-stage immune-oncology imaging company ImaginAb said it signed a multi-year non-exclusive license agreement with AstraZeneca, which will allow the drugmaker to use its CD8 ImmunoPET technology in clinical trials in North America and Europe.

ImaginAb's technology uses radiologic imaging to track whether CD8-expressing T cells have infiltrated a patient's tumor. The technology could potentially enable the development of personalized treatments.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.